Evaluation of Pain Treatment After Total Knee Arthroplasty

Part of paid clinical trials in Bellaire, Texas.

Sponsor
Vertex Pharmaceuticals Incorporated
Study ID
NCT07538570
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Suzetrigine — DRUG
    Tablets for oral administration.
  • Placebo — DRUG
    Placebo matched to SUZ for oral administration

Study Details

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Key Dates

Start date
Apr 24, 2026
Status verified
Apr 2026
Primary completion
Jan 30, 2027
Completion
Jan 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Suzetrigine (SUZ)
    Participants will receive SUZ for 14 days.
  • Placebo Comparator: Placebo
    Participants will receive placebo matched to SUZ for 14 days

Primary Outcome Measure

Proportion of Participants who Remain Opioid-Free [ Time Frame: From Day 1 up to Day 14 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Legent Orthopedic and Spine HospitalBellaireTexas77401-
Memorial Hermann Village OfficeHoustonTexas77043-

Find similar trials in Bellaire, TX

By research site
Legent Orthopedic and Spine Hospital· Bellaire, TXMemorial Hermann Village Office· Houston, TX

Related Studies